晚期非小细胞肺癌在常规临床实践中的个性化治疗
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.
作者信息
Pirker Robert, Filipits Martin
机构信息
Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
出版信息
Cancer Metastasis Rev. 2016 Mar;35(1):141-50. doi: 10.1007/s10555-016-9612-6.
Abstract
Personalized treatment of patients with advanced non-small-cell lung cancer based on clinical and molecular tumor features has entered clinical routine practice. The 2015 pathological classification of lung cancer mandates immunohistochemical and molecular analysis. Therapeutic strategies focused on inhibition of angiogenesis and growth factor receptor signaling. Inhibitors of angiogenesis and monoclonal antibodies directed against the epidermal growth factor receptor have shown efficacy in combination with chemotherapy. Mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase have become clinically relevant therapeutic targets. Immune checkpoint inhibitors are also entering routine clinical practice. Identification of predictive biomarkers is essential and faces several challenges including tumor heterogeneity and dynamic changes of tumor features over time. Liquid biopsies may overcome some of these challenges in the future.
摘要
基于临床和分子肿瘤特征的晚期非小细胞肺癌患者个性化治疗已进入临床常规实践。2015年肺癌病理分类要求进行免疫组织化学和分子分析。治疗策略集中于抑制血管生成和生长因子受体信号传导。血管生成抑制剂和针对表皮生长因子受体的单克隆抗体已显示出与化疗联合使用的疗效。表皮生长因子受体和间变性淋巴瘤激酶的突变已成为具有临床意义的治疗靶点。免疫检查点抑制剂也正在进入常规临床实践。预测性生物标志物的识别至关重要，并且面临包括肿瘤异质性和肿瘤特征随时间动态变化在内的若干挑战。液体活检未来可能会克服其中一些挑战。
相似文献
1
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.晚期非小细胞肺癌在常规临床实践中的个性化治疗
Cancer Metastasis Rev. 2016 Mar;35(1):141-50. doi: 10.1007/s10555-016-9612-6.
2
Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.针对非小细胞肺癌的靶向治疗——最新进展与未来展望。
Int J Cancer. 2016 Jun 1;138(11):2549-61. doi: 10.1002/ijc.29915. Epub 2015 Dec 15.
3
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.表皮生长因子受体（EGFR）突变或ALK基因重排的晚期非小细胞肺癌的治疗：意大利胸科肿瘤学协会国际专家小组会议结果
Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27.
4
Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.西妥昔单抗单药治疗表皮生长因子受体酪氨酸激酶抑制剂治疗后晚期非小细胞肺癌患者。
J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0.
5
Targeting the MET gene for the treatment of non-small-cell lung cancer.针对 MET 基因治疗非小细胞肺癌。
Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1.
6
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
7
Epidermal growth factor receptor: pathway, therapies, and pipeline.表皮生长因子受体：通路、治疗方法和研发管线。
Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007.
8
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.早期非小细胞肺癌的个性化治疗：表皮生长因子受体抑制剂的挑战性作用
Future Oncol. 2015;11(8):1259-74. doi: 10.2217/fon.14.320.
9
Update on systemic therapy of advanced non-small-cell lung cancer.晚期非小细胞肺癌全身治疗的最新进展
Expert Rev Anticancer Ther. 2014 Oct;14(10):1189-203. doi: 10.1586/14737140.2014.940327. Epub 2014 Aug 7.
10
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.表皮生长因子受体突变和间变性淋巴瘤激酶阳性非小细胞肺癌的辅助治疗：现有数据和未来前景。
Lung Cancer. 2015 Oct;90(1):1-7. doi: 10.1016/j.lungcan.2015.07.016. Epub 2015 Jul 30.
引用本文的文献
1
Simultaneous Occurrence of Mutations in Mutant NSCLC: Case Reports.突变型非小细胞肺癌中同时发生的突变：病例报告
JTO Clin Res Rep. 2024 Sep 7;5(12):100719. doi: 10.1016/j.jtocrr.2024.100719. eCollection 2024 Dec.
2
Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report.奥希替尼治疗一名具有两种常见表皮生长因子受体（EGFR）突变及伴发MET外显子14跳跃突变的晚期非小细胞肺癌患者：病例报告
Cancer Manag Res. 2023 Jul 12;15:645-650. doi: 10.2147/CMAR.S412199. eCollection 2023.
3
Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer.病例报告：不同病灶中耐药机制的异质性共同介导了表皮生长因子受体（EGFR）突变的非小细胞肺癌对一线埃克替尼的获得性耐药。
Front Med (Lausanne). 2022 Jul 7;9:906364. doi: 10.3389/fmed.2022.906364. eCollection 2022.
4
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective study.中国不可切除的IIIB/IV期非小细胞肺癌患者的治疗策略、总生存期及相关危险因素（2015 - 2017年）：一项多中心前瞻性研究
Lancet Reg Health West Pac. 2022 Apr 11;23:100452. doi: 10.1016/j.lanwpc.2022.100452. eCollection 2022 Jun.
5
The co-mutation of and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients.在中国非小细胞肺癌患者中，[具体基因]与肿瘤相关基因的共同突变导致预后更差以及肿瘤突变负荷水平更高。 （原文中“and”前面缺少具体基因信息）
J Thorac Dis. 2022 Jan;14(1):185-193. doi: 10.21037/jtd-21-1921.
6
Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.非小细胞肺癌非基因特异性化疗的个体化医学
Acta Pharm Sin B. 2021 Nov;11(11):3406-3416. doi: 10.1016/j.apsb.2021.02.003. Epub 2021 Feb 10.
7
Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports.持续使用表皮生长因子受体酪氨酸激酶抑制剂治疗的射频消融术可延长对表皮生长因子受体酪氨酸激酶抑制剂产生获得性耐药的表皮生长因子受体突变型晚期肺癌的疾病控制时间：两例病例报告
Onco Targets Ther. 2020 Jul 13;13:6789-6793. doi: 10.2147/OTT.S257431. eCollection 2020.
8
Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil.巴西 73167 例肺癌患者的肿瘤-淋巴结-转移分期和治疗模式。
J Bras Pneumol. 2020 Jan 20;46(1):e20180251. doi: 10.1590/1806-3713/e20180251. eCollection 2020.
9
Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.巴西南部肺腺癌患者预测生物标志物分析显示与该国其他地区不同的特征。
J Glob Oncol. 2019 Sep;5:1-9. doi: 10.1200/JGO.19.00174.
10
Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification.免疫富集非小细胞肺癌基线活检进行多重分析，确定预后免疫检查点组合进行患者分层。
J Immunother Cancer. 2019 Mar 28;7(1):86. doi: 10.1186/s40425-019-0544-x.
本文引用的文献
1
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.非小细胞肺癌患者血浆中循环肿瘤DNA的表皮生长因子受体突变检测：支持AZD9291临床开发的领先技术的跨平台比较
Lung Cancer. 2015 Dec;90(3):509-15. doi: 10.1016/j.lungcan.2015.10.004. Epub 2015 Oct 9.
2
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.通过肿瘤活检与非侵入性血液分析检测T790M（获得性耐药表皮生长因子受体突变）
Clin Cancer Res. 2016 Mar 1;22(5):1103-10. doi: 10.1158/1078-0432.CCR-15-1031. Epub 2015 Oct 7.
3
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
4
Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.表皮生长因子受体突变阳性非小细胞肺癌在中欧真实世界环境中的研究：INSIGHT 研究。
J Thorac Oncol. 2015 Sep;10(9):1370-1374. doi: 10.1097/JTO.0000000000000621.
5
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.2015 年世界卫生组织肺肿瘤分类：自 2004 年分类以来遗传、临床和放射学进展的影响。
J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.
6
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
7
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.耐昔妥珠单抗联合吉西他滨和顺铂与吉西他滨和顺铂单药一线治疗局部晚期或转移性鳞状非小细胞肺癌患者（SQUIRE）：一项开放标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
8
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.表皮生长因子受体（EGFR）突变与对不可逆嘧啶类EGFR抑制剂的耐药性
Clin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6.
9
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.获得性表皮生长因子受体（EGFR）C797S突变介导携带EGFR T790M的非小细胞肺癌对AZD9291耐药。
Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.
10
Rociletinib in EGFR-mutated non-small-cell lung cancer.罗西替尼治疗 EGFR 突变型非小细胞肺癌。
N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.
Zotero 插件